^
Association details:
| Biomarker: | TP53 expression |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Regimen: | R-CHOP (cyclophosphamide + doxorubicin hydrochloride + + Rituxan (rituximab) + vincristine) |
| Direction: | Resistant |
Evidence:
Source:
Title:
TP53 Expression Correlates with TP53 Mutations and Is an Independent Predictor of Clinical Outcome in Patients with DLBCL Treated with R-CHOP
Published date:
11/06/2019
Excerpt:
We analyzed 347 newly diagnosed de novo DLBCL cases uniformly treated with R-CHOP in British Columbia....Both p53mut and TP53+ were associated with poor overall survival (OS) (p=0.004 and p=0.007, respectively) and disease-specific survival (DSS) (p=0.003 and p=0.001, respectively).
DOI:
https://doi.org/10.1182/blood-2019-121943
